Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium neuromuscular blockade in sickle cell patients undergoing elective laparoscopic surgery in Cameroon
PACTR202011894723114Phase 4Unknown
- Sponsor
- ARES Scientific
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rocuronium in sickle cell disease (SCD) (2 arms), sponsored by ARES Scientific. Primary endpoints: Onset time of action of rocuronium, Intubation conditions at 2 minutes after induction and 4 more. Status: unknown.
02
Drugs
rocuronium
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202011894723114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202011894723114.